Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| IMU University, Malaysia | OTHER |
| Universiti Putra Malaysia | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
There is existing evidence to show that vegetable oils having unsaturated fatty acids in the sn-2 position with predominantly palmitic acid (C16:0) or stearic acid (C18:0) in the sn-1 and sn-3 positions of fat molecules do not raise serum cholesterol levels. These observations have come to be known as or explained by the "sn-2 hypothesis". New evidence have also emerged to show that saturated fatty acids (C16:0, C18:0) in the sn-1 and -3 positions reduces fat deposition in a rat model. Therefore, further studies in humans are warranted to confirm these earlier findings.
Fats and oils are made up of >90% triacylglycerol (TAG)- fat molecules which consist of a glycerol backbone to which 3 esterified fatty acids are attached. The positions of fatty acid attachment are referred to by stereospecific numbers, sn -1, -2 and -3. Early evidence shown that the unique stereospecificity of fatty acid distribution on the palm fat molecule conferred health benefits in that it inhibited experimental atherosclerosis in the rabbit model.
In vegetable oils, oleic acid [a monounsaturated fatty acid (MUFA)] is predominantly situated at the sn-2 position, while in animals fats it is predominantly palmitic acid or stearic acid (C16:0 or C18:0-saturated fat) that is situated there. Even though palm olein and lard have similar proportions of saturated fatty acid (SFA), MUFA and polyunsatuared fatty acid (PUFA), they differ significantly in their positional distribution on the TAG molecule. Palm olein TAG contains only 7-11 % palmitic acid at the sn-2 position while about 87% is unsaturated fatty acids (oleic acid and linoleic acid). Lard has the highest amount of palmitic acid in the sn-2 position at 70%. On the other hand, in human milk, palmitic acid is predominantly in sn-2 (53-57 %) while cow milk fat contains less palmitic acid (38 %) there. It is now believed that the distribution of fatty acids in the TAG is more important than the fatty acid composition alone in conferring the oils' 'saturated' or 'unsaturated' properties.
In this proposed study, the effects on the outcome measures investigated of different fatty acids (palmitic acid, oleic acid, linoleic acid) at the sn-1, sn-2 and sn-3 positions of the TAG molecule in three different test fats will be investigated.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Test Fat Blue | Experimental | 16 weeks interventions |
|
| Test Fat Green | Experimental | 16 weeks interventions |
|
| Test Fat Red | Experimental | 16 weeks interventions |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Test Fat Blue | Other | Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Blue which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Change of liver fat content | measured by magnetic resonance imaging (MRI) scan | week 0 (baseline) and week 16 |
| Measure | Description | Time Frame |
|---|---|---|
| Change of body mass index (BMI) | measured by Tanita Segmental Body Fat Analysis | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of waist circumference | week 0 (baseline), week 4, week 8, week 12 and week 16 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Choo Yuen May, PhD | MPOB | Study Chair |
| Augustine Ong Soon Hock, PhD | MPOB | Principal Investigator |
| Voon Phooi Tee, PhD | MPOB | Principal Investigator |
| Tony Ng Kock Wai, PhD | IMU | Principal Investigator |
| Verna Lee Kar Man, PhD | IMU | Principal Investigator |
| Norhaizan Mohd Esa, PhD | UPM | Principal Investigator |
| Teh Soek Sin, PhD | MPOB | Principal Investigator |
| Yap Sia Yen, PhD | MPOB | Principal Investigator |
| Ng Yen Teng, Bsc | MPOB | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Test Fat Green | Other | Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Green which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks. |
|
| Test Fat Red | Other | Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Red which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks. |
|
| Change of body fat distribution/content | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of visceral adiposity index (VAI) | analysed by visceral adiposity index (VAI) | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of body adiposity index (BAI) | analysed by visceral body adiposity index (BAI) | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of serum leptin | analysed by enzyme-linked immunosorbent assay (ELISA) development kits | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of serum total cholesterol (TC) | analyzed enzymatically by Siemens Advia 2400 Chemistry Analyzer | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of serum high-density lipoprotein cholesterol (HDLC) | analyzed enzymatically by Siemens Advia 2400 Chemistry Analyzer | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of serum triacylglycerie (TAG) | analyzed enzymatically by Siemens Advia 2400 Chemistry Analyzer | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of serum low-density lipoprotein (LDLC) | analyzed enzymatically by Siemens Advia 2400 Chemistry Analyzer | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of serum lipoprotein ration (TC/HDLC) | analyzed enzymatically by Siemens Advia 2400 Chemistry Analyzer | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of serum HDL-subfractions | measured by Lipoprint® HDL Subfractions Test | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of serum LDL-subfractions | measured by Lipoprint® LDL Subfractions Test | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of serum Apolipoprotein A | measured by Siemens Advia 2400 Chemistry Analyzer | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of serum Apolipoprotein B | measured by Siemens Advia 2400 Chemistry Analyzer | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of serum Lp (a) | measured by Siemens Advia 2400 Chemistry Analyzer | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Faecal fatty acid composition (FAC) | FAC of faecal extracted fat measured by gas chromatography (GC) | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of visceral adipose tissue | measured by MRI | week 0 (baseline) and week 16 |
| Change of subcutaneous adipose tissue | measured by MRI | week 0 (baseline) and week 16 |
| Change of serum interleukin-6 (IL-6) | analysed by ELISA development kits | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of serum tumor necrosis factor alpha (TNF-α) | analysed by ELISA development kits | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Change of serum high-sensitivity C-reactive protein (hsCRP) | analysed by ELISA development kits | week 0 (baseline), week 4, week 8, week 12 and week 16 |
| Systolic and diastolic blood pressure | measured by blood pressure meter | week 0 (baseline), week 4, week 8, week 12 and week 16 |